Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 121

1.

Increased myo-inositol in parietal white and gray matter as a biomarker of poor prognosis in neuropsychiatric lupus: a case report.

Castillo AG, Alonso J, Martínez-Valle F, Alonso-Vila S, Garrido-Castro A, Vilardell-Tarrés M, Rovira A, Ordi-Ros J.

Lupus. 2014 Sep;23(10):1073-8. doi: 10.1177/0961203314534303. Epub 2014 May 15.

PMID:
25118052
[PubMed - in process]
2.

Lack of replication of higher genetic risk load in men than in women with systemic lupus erythematosus.

Alonso-Perez E, Suarez-Gestal M, Calaza M, Blanco FJ, Suarez A, Santos MJ, Papasteriades C, Carreira P, Pullmann R, Ordi-Ros J, Marchini M, Skopouli FN, Bijl M, Barrizone N, Sebastiani GD, Migliaresi S, Witte T, Lauwerys BR, Kovacs A, Ruzickova S, Gomez-Reino JJ, Gonzalez A.

Arthritis Res Ther. 2014 Jun 19;16(3):R128. [Epub ahead of print]

PMID:
24946689
[PubMed - as supplied by publisher]
Free PMC Article
3.

Neutrophil gelatinase-associated lipocalin as a biomarker for lupus nephritis.

Torres-Salido MT, Cortés-Hernández J, Vidal X, Pedrosa A, Vilardell-Tarrés M, Ordi-Ros J.

Nephrol Dial Transplant. 2014 Apr 7. [Epub ahead of print]

PMID:
24711435
[PubMed - as supplied by publisher]
4.

Idiopathic retroperitoneal fibrosis: IgG4 infiltration in a cohort of Spanish patients.

Fernández-Codina A, Martínez-Valle F, Castro-Marrero J, De Torres I, Vilardell-Tarrés M, Ordi-Ros J.

Rheumatol Int. 2014 Jan 10. [Epub ahead of print] No abstract available.

PMID:
24408251
[PubMed - as supplied by publisher]
5.

Clinical and serological findings associated with the expression of ITGAL, PRF1, and CD70 in systemic lupus erythematosus.

Balada E, Castro-Marrero J, Felip L, Ordi-Ros J, Vilardell-Tarrés M.

Clin Exp Rheumatol. 2014 Jan-Feb;32(1):113-6. Epub 2013 Nov 15.

PMID:
24238281
[PubMed - in process]
6.

Cardiac manifestations other than valvulopathy in antiphospholipid syndrome: long-time echocardiography follow-up study.

Pardos-Gea J, Avegliano G, Evangelista A, Vilardell M, Ordi-Ros J.

Int J Rheum Dis. 2013 Oct 17. doi: 10.1111/1756-185X.12191. [Epub ahead of print]

PMID:
24131635
[PubMed - as supplied by publisher]
7.

[Current therapeutic indications of thalidomide and lenalidomide].

Ordi-Ros J, Cosiglio FJ.

Med Clin (Barc). 2014 Apr 22;142(8):360-4. doi: 10.1016/j.medcli.2013.04.038. Epub 2013 Jul 3. Spanish.

PMID:
23830554
[PubMed - in process]
8.

Idiopathic retroperitoneal fibrosis: a clinicopathological study in 24 Spanish cases.

Fernández-Codina A, Martínez-Valle F, Castro-Marrero J, Detorres I, Vilardell-Tarrés M, Ordi-Ros J.

Clin Rheumatol. 2013 Jun;32(6):889-93. doi: 10.1007/s10067-013-2225-3. Epub 2013 Mar 21.

PMID:
23515600
[PubMed - indexed for MEDLINE]
9.

[Procalcitonin as a biomarker in patients with systemic lupus erythematosus].

Consiglio FJ, Ordi Ros J.

Med Clin (Barc). 2013 Mar 2;140(5):214-6. doi: 10.1016/j.medcli.2012.10.009. Epub 2012 Dec 29. Spanish. No abstract available.

PMID:
23276619
[PubMed - indexed for MEDLINE]
10.

Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus.

Cortés-Hernández J, Avila G, Vilardell-Tarrés M, Ordi-Ros J.

Arthritis Res Ther. 2012 Dec 7;14(6):R265. doi: 10.1186/ar4111.

PMID:
23217273
[PubMed - in process]
Free PMC Article
11.

Further evidence of subphenotype association with systemic lupus erythematosus susceptibility loci: a European cases only study.

Alonso-Perez E, Suarez-Gestal M, Calaza M, Ordi-Ros J, Balada E, Bijl M, Papasteriades C, Carreira P, Skopouli FN, Witte T, Endreffy E, Marchini M, Migliaresi S, Sebastiani GD, Santos MJ, Suarez A, Blanco FJ, Barizzone N, Pullmann R, Ruzickova S, Lauwerys BR, Gomez-Reino JJ, Gonzalez A; European Consortium of SLE DNA Collections.

PLoS One. 2012;7(9):e45356. doi: 10.1371/journal.pone.0045356. Epub 2012 Sep 26.

PMID:
23049788
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Associations between the expression of epigenetically regulated genes and the expression of DNMTs and MBDs in systemic lupus erythematosus.

Balada E, Castro-Marrero J, Felip L, Ordi-Ros J, Vilardell-Tarrés M.

PLoS One. 2012;7(9):e45897. doi: 10.1371/journal.pone.0045897. Epub 2012 Sep 21. Erratum in: PLoS One. 2012; 7(10): 10.1371/annotation/e5e824bf-e57f-4225-bfa0-cc32241a1ff0.

PMID:
23029299
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Bias in effect size of systemic lupus erythematosus susceptibility loci across Europe: a case-control study.

Alonso-Perez E, Suarez-Gestal M, Calaza M, Sebastiani GD, Pullmann R, Papasteriades C, Kovacs A, Skopouli FN, Bijl M, Suarez A, Marchini M, Migliaresi S, Carreira P, Ordi-Ros J, Witte T, Ruzickova S, Santos MJ, Barizzone N, Blanco FJ, Lauwerys BR, Gomez-Reino JJ, Gonzalez A; European Consortium of SLE DNA Collections.

Arthritis Res Ther. 2012 Apr 27;14(2):R94.

PMID:
22541939
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Acquired haemophilia A. First line treatment with calcineurin inhibitors and steroid pulses: a 10-year follow-up study.

Pardos-Gea J, Altisent C, Parra R, Vilardell-Tarrès M, Ordi-Ros J.

Haemophilia. 2012 Sep;18(5):789-93. doi: 10.1111/j.1365-2516.2012.02772.x. Epub 2012 Mar 19.

PMID:
22429259
[PubMed - indexed for MEDLINE]
15.

Anti-ganglioside antibodies in patients with systemic lupus erythematosus and neurological manifestations.

Labrador-Horrillo M, Martinez-Valle F, Gallardo E, Rojas-Garcia R, Ordi-Ros J, Vilardell M.

Lupus. 2012 May;21(6):611-5. doi: 10.1177/0961203312436856. Epub 2012 Feb 9.

PMID:
22323340
[PubMed - indexed for MEDLINE]
16.

Association of systemic lupus erythematosus clinical features with European population genetic substructure.

Alonso-Perez E, Suarez-Gestal M, Calaza M, Witte T, Papasteriades C, Marchini M, Migliaresi S, Kovacs A, Ordi-Ros J, Bijl M, Santos MJ, Ruzickova S, Pullmann R, Carreira P, Skopouli FN, D'Alfonso S, Sebastiani GD, Suarez A, Blanco FJ, Gomez-Reino JJ, Gonzalez A; European Consortium of SLE DNA Collections.

PLoS One. 2011;6(12):e29033. doi: 10.1371/journal.pone.0029033. Epub 2011 Dec 14.

PMID:
22194982
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome.

Cortés-Hernández J, Torres-Salido M, Castro-Marrero J, Vilardell-Tarres M, Ordi-Ros J.

Br J Dermatol. 2012 Mar;166(3):616-23. doi: 10.1111/j.1365-2133.2011.10693.x. Epub 2012 Jan 19.

PMID:
21999437
[PubMed - indexed for MEDLINE]
18.

The PTPN22*R620W polymorphism does not confer genetic susceptibility to antiphospholipid syndrome in the Spanish population.

Castro-Marrero J, Balada E, Vilardell-Tarrés M, Ordi-Ros J.

Int J Immunogenet. 2011 Dec;38(6):529-31. doi: 10.1111/j.1744-313X.2011.01038.x. Epub 2011 Sep 19.

PMID:
21923648
[PubMed - indexed for MEDLINE]
19.

Xenotropic murine leukemia virus-related virus (XMRV) in patients with systemic lupus erythematosus.

Balada E, Castro-Marrero J, Felip L, Vilardell-Tarrés M, Ordi-Ros J.

J Clin Immunol. 2011 Aug;31(4):584-7. doi: 10.1007/s10875-011-9535-5. Epub 2011 Apr 21.

PMID:
21509625
[PubMed - indexed for MEDLINE]
20.

Enhanced transcript levels of CD48 in CD4⁺ T cells from systemic lupus erythematosus patients.

Balada E, Castro-Marrero J, Pujol AP, Torres-Salido MT, Vilardell-Tarrés M, Ordi-Ros J.

Immunobiology. 2011 Sep;216(9):1034-7. doi: 10.1016/j.imbio.2011.03.004. Epub 2011 Mar 12.

PMID:
21474199
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk